 |
Astellas and Medivation Announce Submission of Application for Marketing Approval of Enzalutamide, an Oral Androgen Receptor Inhibitor, in Japan
May 24, 2013
|
60.3 KB |
|
| |
TOKYO & SAN FRANCISCO--(BUSINESS WIRE)--
Astellas Pharma Inc. (TOKYO: 4503) and Medivation, Inc. (NASDAQ: MDVN)
today announced that Astellas has submitted an application for marketing
approval of enzalutamide (generic name) to the Ministry of Health,
Labour and Welfare in Japan for the treatment of prostate canc...
|
|
Medivation Names Stephen Kelsey Senior Vice President of New Projects
May 13, 2013
|
10.1 KB |
|
| |
SAN FRANCISCO, CA -- (Marketwired) -- 05/13/13 --
Medivation, Inc. (NASDAQ: MDVN) today announced that Stephen M. Kelsey, M.D., F.R.C.P., F.R.C.Path. will join Medivation in the newly-created position of senior vice president of new projects, reporting to Dr. David Hung, M.D., Medivation's president and chief executive officer.
"Ste...
|
|
Medivation Reports First Quarter Financial Results and Provides Corporate Update
May 9, 2013
|
72.1 KB |
|
| |
SAN FRANCISCO, CA -- (Marketwired) -- 05/09/13 --
Medivation, Inc. (NASDAQ: MDVN) today provided a corporate update and reported its financial results for the first quarter ended March 31, 2013. Net sales of XTANDI® (enzalutamide) capsules for the quarter, as reported by Astellas Pharma Inc., were $75.4 million, an increase of $18.0 millio...
|
|
Medivation Announces Participation at Upcoming Investor Conferences
May 6, 2013
|
9.6 KB |
|
| |
SAN FRANCISCO, CA -- (Marketwired) -- 05/06/13 --
Medivation, Inc. (NASDAQ: MDVN) today announced that it will present at the following conferences:
David Hung, M.D., president and chief executive officer, will present at the UBS Global Healthcare Conference on May 20 at 1pm ET at the Grand Hyatt in New York, NY.
...
|
|
Medivation Elects Wendy L. Yarno to Board of Directors
Apr 29, 2013
|
9.5 KB |
|
| |
SAN FRANCISCO, CA -- (Marketwired) -- 04/29/13 --
Medivation, Inc. (NASDAQ: MDVN) today announced that Wendy Yarno has been elected to the Company's Board of Directors. Ms. Yarno has over 26 years of experience in the pharmaceutical industry at Merck & Co. Inc., holding a number of executive positions in the marketing, sales and human resources...
|
|
POSITIVE CHMP OPINION FOR XTANDI (ENZALUTAMIDE) IN ADVANCED PROSTATE CANCER
Apr 26, 2013
|
64.6 KB |
|
| |
Enzalutamide recommended for approval in the European Union (EU) for
the treatment of adult men with metastatic castration-resistant prostate
cancer whose disease has progressed on or after docetaxel therapy
CHERTSEY, England & SAN FRANCISCO, CA--(BUSINESS WIRE)--
Today, Astellas Pharma Euro...
|
|
Medivation Announces First Quarter 2013 Financial Results Teleconference on May 9, 2013
Apr 25, 2013
|
9.6 KB |
|
| |
SAN FRANCISCO, CA -- (Marketwired) -- 04/25/13 --
Medivation, Inc. (NASDAQ: MDVN) today announced that it will host a live teleconference with management to discuss first quarter 2013 financial results and provide a general business update on May 9, 2013 at 4:30 p.m. Eastern Time. A press release for the first quarter of 2013 will be released a...
|
|
Medivation Elects Dawn Graham to Board of Directors
Apr 23, 2013
|
58.4 KB |
|
| |
SAN FRANCISCO, CA -- (Marketwired) -- 04/23/13 --
Medivation, Inc. (NASDAQ: MDVN) today announced that Dawn Graham has been elected to the Company's Board of Directors. Ms. Graham joins Medivation following a 23-year career in pharmaceutical commercial leadership positions at Merck & Co. Inc., from which she retired in 2011 as President of Euro...
|
|
Medivation and Astellas Provide Update on PREVAIL
Apr 1, 2013
|
60.5 KB |
|
| |
SAN FRANCISCO, CA and TOKYO -- (Marketwire) -- 04/01/13 --
Medivation, Inc. (NASDAQ: MDVN) and Astellas Pharma Inc. (TSE: 4503) today announced that the companies have established an updated interim analysis plan for the PREVAIL trial, a global Phase 3 clinical trial evaluating XTANDI® (enzalutamide) capsules in men with metastatic castrat...
|
|
Medivation Announces Participation at Upcoming Investor Conference
Mar 6, 2013
|
8.9 KB |
|
| |
SAN FRANCISCO, CA -- (Marketwire) -- 03/06/13 --
Medivation, Inc. (NASDAQ: MDVN) today announced that it will present at the following conference:
Patrick Machado, chief business and financial officer, will present at the Barclays Global Healthcare Conference on March 12 at 1:30pm ET in Miami, FL.
About Medivation
Medivation, Inc. is a bi...
|
|
Medivation Reports Fourth Quarter and Year-End 2012 Financial Results and Provides Corporate Update
Feb 28, 2013
|
23.3 KB |
|
| |
SAN FRANCISCO, CA -- (Marketwire) -- 02/28/13 --
Medivation, Inc. (NASDAQ: MDVN) today provided a corporate update and reported its financial results for the fourth quarter and year ended December 31, 2012. Net sales of XTANDI® (enzalutamide) capsules for the quarter, as reported by Astellas Pharma Inc., were $57.4 million, which represent...
|
|
Medivation and Astellas Provide Additional Support to Metastatic Prostate Cancer Patients Through Donations to Independent Non-Profit Patient Assistance Organization
Feb 25, 2013
|
11.5 KB |
|
| |
SAN FRANCISCO, CA and NORTHBROOK, IL -- (Marketwire) -- 02/25/13 --
Medivation Inc. (NASDAQ: MDVN) and Astellas Pharma US, Inc., a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (TSE: 4503), announced that the companies are providing additional support to the Chronic Disease Fund (CDF). CDF uses charitable donations to help eligible men wi...
|
|
Medivation Announces Fourth Quarter and Year-End 2012 Financial Results Teleconference on February 28, 2013
Feb 14, 2013
|
9.6 KB |
|
| |
SAN FRANCISCO, CA -- (Marketwire) -- 02/14/13 --
Medivation, Inc. (NASDAQ: MDVN) today announced that it will host a live teleconference with management to discuss fourth quarter and year-end 2012 financial results and provide a general business update on February 28, 2013 at 4:30 p.m. Eastern Time. A press release for the fourth quarter and ye...
|
|
Enzalutamide Data Presented at ASCO GU Symposium
Feb 13, 2013
|
70.7 KB |
|
| |
SAN FRANCISCO, CA and TOKYO -- (Marketwire) -- 02/13/13 --
Medivation, Inc. (NASDAQ: MDVN) and Astellas Pharma Inc. (Tokyo: 4503) announced that data for enzalutamide, an oral androgen receptor inhibitor, will be presented at the American Society of Clinical Oncology (ASCO) 2013 Genitourinary (GU) Cancers Symposium in Orlando, Florida.
...
|
|
Medivation Announces Participation at Upcoming Investor Conference
Feb 6, 2013
|
8.9 KB |
|
| |
SAN FRANCISCO, CA -- (Marketwire) -- 02/06/13 --
Medivation, Inc. (NASDAQ: MDVN) today announced that it will present at the following conference:
Patrick Machado, chief business and financial officer, will present at the Leerink Swann Global Healthcare Conference on February 13 at 8:30am ET in New York, NY.
About Medivation
Medivation, I...
|
|
Medivation Elects Kathryn Falberg to Board of Directors
Feb 4, 2013
|
9.7 KB |
|
| |
SAN FRANCISCO, CA -- (Marketwire) -- 02/04/13 --
Medivation, Inc. (NASDAQ: MDVN) today announced that Kathryn E. Falberg has been elected to the Company's Board of Directors. Ms. Falberg will also serve as chair of the Audit Committee.
"We are delighted to welcome an experienced pharmaceutical executive of Kate's caliber to Mediv...
|
|
Enzalutamide Data to Be Presented at ASCO GU Symposium
Jan 30, 2013
|
62.9 KB |
|
| |
SAN FRANCISCO, CA and TOKYO -- (Marketwire) -- 01/30/13 --
Medivation, Inc. (NASDAQ: MDVN) and Astellas Pharma Inc. (TSE: 4503) today announced that six abstracts related to enzalutamide research will be presented on Thursday, February 14 at the American Society of Clinical Oncology (ASCO) 2013 Genitourinary (GU) Cancers Symposium in Orlando, F...
|
|
Medivation Announces Participation at Upcoming Investor Conferences
Nov 29, 2012
|
9.1 KB |
|
| |
SAN FRANCISCO, CA -- (Marketwire) -- 11/29/12 --
Medivation, Inc. (NASDAQ: MDVN) today announced that it will present at the following conferences:
David Hung, M.D., president and chief executive officer, will present at the Deutsche Bank BioFEST Conference on December 3 at 9:35am Eastern Time in Boston, MA.
David Hung, M.D.,...
|
|
Medivation Reports Third Quarter Financial Results and Provides Corporate Update
Nov 9, 2012
|
23.5 KB |
|
| |
SAN FRANCISCO, CA -- (Marketwire) -- 11/09/12 --
Medivation, Inc. (NASDAQ: MDVN) today provided a corporate update and reported its financial results for the third quarter ended September 30, 2012. Net sales of XTANDI® (enzalutamide) capsules for the quarter, as reported by Astellas Pharma Inc., were $14.1 million, which represents the fir...
|
|
Medivation Announces Participation at Upcoming Investor Conferences
Nov 7, 2012
|
9.2 KB |
|
| |
SAN FRANCISCO, CA -- (Marketwire) -- 11/07/12 --
Medivation, Inc. (NASDAQ: MDVN) today announced that it will present at the following conferences:
Patrick Machado, chief business and financial officer, will present at the Jefferies 2012 Global Healthcare Conference on November 14 at 3:00p.m. in London.
David Hung, M.D., pres...
|
|
|